65,437 trials
Papillomavirus Infections · Coronavirus Disease (COVID-19)
Primary: Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV) — 2198.5; 1806.8; 1517.6; 1138.2 mMU/mL
Human Immunodeficiency Virus
Primary: Number of Participants With Solicited Adverse Events (AEs) Through 7 Days Post Dose 1 of Study Intervention — 155; 49; 132; 109 Participants
Hyperemia Eye
Primary: Intraocular Pressure (IOP) Increment — 14.00; 13.57; 13.47; 13.25 mmhg
Presbyopia
Primary: Overall Lens Handling — 96.0; 90.0 score on a scale
Obesity, Visceral · Obesity; Endocrine
Primary: Visceral Fat Loss (cm3) — -628 cm3
Spinal Cord Injury
Primary: System Usability Scale — 4; 7 score on a Likert scale
Severe Aplastic Anemia (SAA)
Primary: Complete Response (CR) Rate at Week 26 — 16.7; 25; 15.4; 0 percentage of participants
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16. — 100…
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
HIV · Hypercholesterolaemia
Primary: Percentage Change From Baseline in Total Cholesterol at 12 Weeks. — 8.7; 21.4 Percentage Change (%) — p=0.003
Chronic Pain
Primary: Recruitment Feasibility (Ability) — 92 Participants
Heart Failure
Primary: Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. — 34.0; 29.8; 22.6; 30.1 mL/mg
Dry Eye
Primary: Ocular Surface Disease Index (OSDI) — 48.9; 50.3 score on a scale
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
HIV-1-infection · Elevated Cardiovascular Risk
Primary: Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel. — 0.95…